353 related articles for article (PubMed ID: 10778729)
1. Progressive disease in children with medulloblastoma/PNET during preradiation chemotherapy.
Tornesello A; Mastrangelo S; Piciacchia D; Bembo V; Colosimo C; Di Rocco C; Mastrangelo R
J Neurooncol; 1999; 45(2):135-40. PubMed ID: 10778729
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
Strother D; Ashley D; Kellie SJ; Patel A; Jones-Wallace D; Thompson S; Heideman R; Benaim E; Krance R; Bowman L; Gajjar A
J Clin Oncol; 2001 May; 19(10):2696-704. PubMed ID: 11352962
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859
[TBL] [Abstract][Full Text] [Related]
4. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.
Prados MD; Wara W; Edwards MS; Ater J; Rabbit J; Lamborn K; Davis R; Levin VA
Pediatr Neurosurg; 1996 Oct; 25(4):174-81. PubMed ID: 9293544
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor.
Sung KW; Yoo KH; Cho EJ; Koo HH; Lim DH; Shin HJ; Ahn SD; Ra YS; Choi ES; Ghim TT
Pediatr Blood Cancer; 2007 Apr; 48(4):408-15. PubMed ID: 17066462
[TBL] [Abstract][Full Text] [Related]
6. Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor--results of a pilot study.
Sawamura Y; Ikeda J; Ishii N; Kato T; Tada M; Abe H; Shirato H
Neurol Med Chir (Tokyo); 1996 Sep; 36(9):632-8. PubMed ID: 8913079
[TBL] [Abstract][Full Text] [Related]
7. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
[TBL] [Abstract][Full Text] [Related]
8. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors.
Allen JC; Donahue B; DaRosso R; Nirenberg A
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1155-61. PubMed ID: 8985038
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.
Saran F; Baumert BG; Creak AL; Warrington AP; Ashley S; Traish D; Brada M
Pediatr Blood Cancer; 2008 Mar; 50(3):554-60. PubMed ID: 17941071
[TBL] [Abstract][Full Text] [Related]
10. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study.
Taylor RE; Bailey CC; Robinson K; Weston CL; Ellison D; Ironside J; Lucraft H; Gilbertson R; Tait DM; Walker DA; Pizer BL; Imeson J; Lashford LS; ;
J Clin Oncol; 2003 Apr; 21(8):1581-91. PubMed ID: 12697884
[TBL] [Abstract][Full Text] [Related]
11. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.
Massimino M; Gandola L; Spreafico F; Luksch R; Collini P; Giangaspero F; Simonetti F; Casanova M; Cefalo G; Pignoli E; Ferrari A; Terenziani M; Podda M; Meazza C; Polastri D; Poggi G; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1031-7. PubMed ID: 16343801
[TBL] [Abstract][Full Text] [Related]
12. The therapy of infantile malignant brain tumors: current status?
Kalifa C; Grill J
J Neurooncol; 2005 Dec; 75(3):279-85. PubMed ID: 16195802
[TBL] [Abstract][Full Text] [Related]
13. Management of medulloblastoma and ependymoma in infants: a single-institution long-term retrospective report.
Massimino M; Gandola L; Cefalo G; Lasio G; Riva D; Fossati-Bellani F; Gianni MC; Luksch R; Tesoro-Tess JD; Lombardi F
Childs Nerv Syst; 2000 Jan; 16(1):15-20. PubMed ID: 10672424
[TBL] [Abstract][Full Text] [Related]
14. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.
Zeltzer PM; Boyett JM; Finlay JL; Albright AL; Rorke LB; Milstein JM; Allen JC; Stevens KR; Stanley P; Li H; Wisoff JH; Geyer JR; McGuire-Cullen P; Stehbens JA; Shurin SB; Packer RJ
J Clin Oncol; 1999 Mar; 17(3):832-45. PubMed ID: 10071274
[TBL] [Abstract][Full Text] [Related]
15. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
16. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
Jennings MT; Cmelak A; Johnson MD; Moots PL; Pais R; Shyr Y
Pediatr Blood Cancer; 2004 Jul; 43(1):46-54. PubMed ID: 15170889
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin in childhood medulloblastoma/PNET: feasibility of an in vivo sensitivity test in an "up-front" study.
Mastrangelo R; Lasorella A; Riccardi R; Colosimo C; Iavarone A; Tornesello A; Mastrangelo S; Ausili-Cefaro G; Di Rocco C
Med Pediatr Oncol; 1995 Mar; 24(3):188-96. PubMed ID: 7838041
[TBL] [Abstract][Full Text] [Related]
18. Medulloblastoma: clinical and biologic aspects.
Packer RJ; Cogen P; Vezina G; Rorke LB
Neuro Oncol; 1999 Jul; 1(3):232-50. PubMed ID: 11550316
[TBL] [Abstract][Full Text] [Related]
19. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy.
Taylor RE; Bailey CC; Robinson KJ; Weston CL; Walker DA; Ellison D; Ironside J; Pizer BL; Lashford LS
Eur J Cancer; 2005 Mar; 41(5):727-34. PubMed ID: 15763649
[TBL] [Abstract][Full Text] [Related]
20. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children's Cancer Study Group (ANZCCSG).
White L; Kellie S; Gray E; Toogood I; Waters K; Lockwood L; Macfarlane S; Johnston H
J Pediatr Hematol Oncol; 1998; 20(2):125-30. PubMed ID: 9544162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
